Published in Clin Pharmacol Ther on May 01, 2008
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res (2010) 2.21
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol (2010) 1.01
Drugs, money and society (Part II). Br J Clin Pharmacol (2010) 0.83
The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: results after one year. BMC Health Serv Res (2013) 0.75
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Clinical guidelines: ways ahead. J Eval Clin Pract (1998) 4.56
Data protection legislation: interpretation and barriers to research. BMJ (2000) 4.43
Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967. Q J Med (1970) 3.71
The Iranian health insurance system; past experiences, present challenges and future strategies. Iran J Public Health (2012) 3.28
Same information, different decisions: the influence of evidence on the management of hypertension in the elderly. Br J Gen Pract (1996) 3.15
Alterations in prescribing by general practitioner fundholders: an observational study. BMJ (1995) 2.96
Why do GPs not implement evidence-based guidelines? A descriptive study. Fam Pract (2001) 2.94
Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet (1966) 2.44
Drugs and the liver. Clin Pharmacol Ther (1998) 2.23
Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet (1967) 2.22
The risk of cardiovascular disease in hypertensive patients. Br J Gen Pract (1997) 2.11
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
Involving consumers in a needs-led research programme: a pilot project. Health Expect (2001) 2.10
Therapeutic conservatism. J R Coll Physicians Lond (1993) 2.02
Pharmacoeconomics: evaluating the evaluators. Br J Clin Pharmacol (1997) 1.89
Hypertension and hyperuricaemia. Lancet (1966) 1.86
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Clinical implications of enzyme induction. Ann N Y Acad Sci (1971) 1.76
Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J (1973) 1.76
Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet (1987) 1.70
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
Kinetics of warfarin absorption in man. Clin Pharmacol Ther (1974) 1.63
Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet (1966) 1.61
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther (1974) 1.61
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM (2003) 1.55
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status. Br J Clin Pharmacol (1994) 1.53
Lifestyle medicines. BMJ (2000) 1.50
Treating mild hypertension. Br Med J (Clin Res Ed) (1985) 1.49
The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol (1987) 1.49
Economic evaluation under managed competition: evidence from the U.K. Soc Sci Med (1997) 1.48
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technol Assess (2003) 1.46
The effect of phenobarbitone-induction on vitamin D metabolism. Clin Sci (1972) 1.46
Postgraduate education in therapeutics: experience in Merseyside. Br Med J (1978) 1.44
Clinical guidelines: development, implementation, and effectiveness. Postgrad Med J (1995) 1.43
A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials (1999) 1.42
Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers. Thorax (1999) 1.42
Hypertension in the young. Q J Med (1967) 1.42
Cost implications of prehospital emergency drug administration. The case of prehospital thrombolytics. Pharmacoeconomics (1996) 1.39
The management of hypertension in the elderly by general practitioners in Merseyside: the rule of halves revisited. Br J Gen Pract (1998) 1.39
The impact of health economics on healthcare delivery: the health economists' perspective. Pharmacoeconomics (2001) 1.39
Therapeutic conservatism. J R Coll Physicians Lond (1993) 1.39
Health care financing in iran; is privatization a good solution? Iran J Public Health (2012) 1.38
Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study. BMJ (1996) 1.37
Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther (2010) 1.32
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
Prescribing costs in general practice fundholding. Lancet (1996) 1.27
Generic prescribing: time to regulate the market? Price rises are a blow to nascent primary care groups. BMJ (2000) 1.26
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess (2004) 1.26
Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS (1994) 1.25
Methyldopa and haemolytic anaemia. Lancet (1966) 1.21
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess (2007) 1.19
Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess (2004) 1.18
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II (1972) 1.16
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ (2001) 1.16
Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers. Br J Clin Pharmacol (1991) 1.14
Therapeutic substitution and therapeutic conservatism as cost-containment strategies in primary care: a study of fundholders and non-fundholders. Br J Gen Pract (1999) 1.13
Combined action of methyldopa and bethanidine. Evidence for a synergistic effect. Lancet (1966) 1.11
Effects of methyldopa on prolactin and growth hormone. Br Med J (1976) 1.11
Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess (2007) 1.10
Addressing barriers to change: an RCT of practice-based education to improve the management of hypertension in the elderly. Br J Gen Pract (1999) 1.10
Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther (1974) 1.09
Clinical guidelines-the hidden costs. BMJ (1999) 1.09
Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet (1967) 1.09
Jogger's blockade. Br Med J (Clin Res Ed) (1982) 1.08
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess (2011) 1.08
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J (2010) 1.07
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart (2005) 1.06
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation. Health Technol Assess (2008) 1.06
Propranolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther (1980) 1.05
Interactions of benzodiazepines with warfarin. Br Med J (1972) 1.05
The UK indicative prescribing scheme: background and operation. Pharmacoeconomics (1992) 1.03
Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol (1991) 1.02
Which beta blocker? Br Med J (Clin Res Ed) (1983) 1.00
Pharmacoeconomics: integrating economic evaluation into clinical trials. Br J Clin Pharmacol (1997) 0.99
Clinical implications of enzyme induction. Basic Life Sci (1975) 0.99
Increased glucuronidation of bilirubin in man and rat by administration of antipyrine (phenazone). Clin Sci Mol Med (1974) 0.98
Concern about records of fibrosing colonopathy study. Lancet (2001) 0.96
The effects of long term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol (1973) 0.95
FHSA medical advisers: friends or foes? BMJ (1992) 0.94
Supply and regulation of medicines. BMJ (2005) 0.94
Advancing the science of medicines regulation: the role of the 21st-century medicines regulator. Clin Pharmacol Ther (2012) 0.94
Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint. Br Med J (Clin Res Ed) (1982) 0.93
The management of Pneumocystis carinii pneumonia. Br J Clin Pharmacol (1999) 0.93
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future. Br J Clin Pharmacol (1994) 0.93
Medication errors in primary care in Riyadh City, Saudi Arabia. East Mediterr Health J (2011) 0.93
Medicines regulation and health technology assessment. Clin Pharmacol Ther (2010) 0.92
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess (2009) 0.91
An Indochinese refugee psychiatric clinic: culturally accepted treatment approaches. Am J Psychiatry (1980) 0.88
Integrating clinical pharmacology in a new problem based medical undergraduate curriculum. Br J Clin Pharmacol (1997) 0.88
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technol Assess (2006) 0.88
Large-dose urography. Is there an optimum dose? Lancet (1967) 0.88
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. Cochrane Database Syst Rev (2005) 0.88
Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics (2001) 0.88
Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia (2006) 0.88
Reporting of adverse drug reactions: practice in the UK. Nurs Times (1998) 0.87
Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process. Clin Pharmacol Ther (2010) 0.87